Document Detail


Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis.
MedLine Citation:
PMID:  14670773     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To evaluate the efficacy and safety of treatment with recombinant growth hormone (rGH) in patients with cystic fibrosis (CF). METHODS: Twenty patients with CF (aged 10-23 years) were randomised to age and sex matched treatment and control groups. The treatment group received daily subcutaneous injections of 1 IU/kg/wk rGH for 12 months. Pulmonary function (forced expiratory volume in one second (FEV1) and airway resistance), exercise capacity measured with a bicycle ergometer, body composition (dual energy x ray absorptiometry), and weight were assessed at the beginning of the study and after 6 and 12 months. RESULTS: rGH treatment did not improve weight and pulmonary function, but lean body mass increased significantly in the treatment group. Exercise capacity increased in the treatment group from 143 (16) W (mean (SD)) to 164 (19) W after 12 months of rGH treatment. CONCLUSION: Treatment of CF patients with rGH for one year improved the exercise capacity significantly but not pulmonary function. The improved exercise capacity needs confirmation in a larger population before such an expensive treatment is justified.
Authors:
A Schibler; R von der Heiden; P Birrer; P E Mullis
Related Documents :
3104053 - Maximal oxygen consumption and pulmonary circulation in patients with chronic bronchitis.
3809753 - Interpretation of changes in dlco and pulmonary function after running five miles.
18512043 - Fuel metabolism during exercise in euglycaemia and hyperglycaemia in patients with type...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Archives of disease in childhood     Volume:  88     ISSN:  1468-2044     ISO Abbreviation:  Arch. Dis. Child.     Publication Date:  2003 Dec 
Date Detail:
Created Date:  2003-12-12     Completed Date:  2004-01-13     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0372434     Medline TA:  Arch Dis Child     Country:  England    
Other Details:
Languages:  eng     Pagination:  1078-81     Citation Subset:  AIM; IM    
Affiliation:
Paediatric Respiratory Medicine, Department of Paediatrics, University of Bern, CH-3010 Bern, Switzerland. andreas_schibler@mater.org.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Body Mass Index
Child
Cystic Fibrosis / drug therapy*
Exercise Tolerance
Female
Follow-Up Studies
Forced Expiratory Volume / physiology
Growth Hormone / therapeutic use*
Humans
Male
Oxygen Consumption / physiology
Prospective Studies
Respiratory System Agents / therapeutic use*
Treatment Outcome
Vital Capacity / physiology
Chemical
Reg. No./Substance:
0/Respiratory System Agents; 9002-72-6/Growth Hormone
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Childhood constipation is not associated with characteristic fingerprint patterns.
Next Document:  Baby walkers: paediatricians' knowledge, attitudes, and health promotion.